Novartis’ (NOVN: VX) Sandoz unit has launched daptomycin for injection 500mg, an AP-rated generic version of Merck & Co’s (NYSE: MRK) Cubicin.
Daptomycin is a medicine used to treat adult patients with complicated skin and skin structure infections caused by Gram-positive bacteria and certain bloodstream infections, including right-sided infective endocarditis.
An antibacterial medicine that is administered intravenously to patients under the direct supervision of their doctor, it can also be used to treat patients with MRSA or superbug infections.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze